Prevenar Antibody Response Into Adulthood Needs Study - FDA Cmte.
Executive Summary
Postmarketing studies of Wyeth-Lederle's 7-valent (4, 6B, 9V, 14, 18c, 19F, 23F) pneumococcal conjugate vaccine Prevenar should evaluate duration of antibody response into adulthood, FDA's Vaccines & Related Biological Products Advisory Committee suggested Nov. 5.
You may also be interested in...
Celexa May Be Hidden Trophy In Warner-Lambert Bidding War
Forest's antidepressant Celexa could either become the centerpiece of a newly created neuropharmaceutical marketing giant or an outlicensing candidate, depending on whether American Home Products or Pfizer prevails in its bid to acquire Warner-Lambert.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011